APOE and androgen insensitivity syndrome: There were 394 AIS patients (394/1929, 20.43%) showed poor function outcome of 90-day mRS (2–6), of whom 147 (147/342, 42.98%) were APOE ε4 carriers and 247 (247/1587, 15.56%) were non-ε4 carriers.